EGFR and non-small cell lung carcinoma: Chemotherapy drugs such as gefitinib and erlotinib (kinase inhibitor) demonstrate good results in NSCLC patients with mutation(s) in EGFR, but resistance to these drugs is common in patients with end-stage disease [98, 99].